Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US7511041 | BAYER HEALTHCARE | Fused azole-pyrimidine derivatives |
May, 2024
(1 year, 8 months from now) | |
USRE46856 | BAYER HEALTHCARE | Substituted 2,3-dihydroimidazo[1,2-c]quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis |
Oct, 2029
(7 years from now) | |
US10383876 | BAYER HEALTHCARE | Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts |
Mar, 2032
(9 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9636344 | BAYER HEALTHCARE | Substituted 2,3-dihydroimidazo[1,2-C]quinazoline salts |
Mar, 2032
(9 years from now) |
Drugs and Companies using COPANLISIB DIHYDROCHLORIDE ingredient
Treatment: Treatment of adult patients with relapsed follicular lymphoma who have received at least two prior systemic therapies
Dosage: POWDER;INTRAVENOUS
Strength | Dosage | Availability |
---|---|---|
60MG/VIAL | POWDER;INTRAVENOUS | Prescription |